Home › Research › Drug development
Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy
Zhao J, Yin F, Ji L, Wang C, Shi C, Liu X, Yang H, Wang X et al.. ACS applied materials & interfaces, 2020-09-16
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a widespread and burdensome neurodegenerative disease; effective diagnostic methods are lacking, and it remains incurable. The clinical applications of nanoscale metal-organic frameworks (NMOFs) have mainly focused on disease diagnosis and treatment of cancer. A multifunctional NMOF-based nanoplatform was successfully developed for the application in AD diagnosis and therapy. The magnetic nanomaterial Fe-MIL-88B-NH 2 was selected to encapsulate methylene blue (MB, a tau aggregation inhibitor) and used as a magnetic resonance contrast material. Subsequently, the targeting reagent 5-amino-3-(pyrrolo[2,3-c]pyridin-1-yl)isoquinoline (defluorinated MK6240, DMK6240) was connected to the surface of Fe-MIL-88B-NH 2 via 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) to enhance hyperphosphorylated tau targeting, resulting in the formation of an advanced drug delivery system, Fe-MIL-88B-NH 2 -NOTA-DMK6240/MB. The surface properties of Fe-MIL-88B-NH 2 -NOTA-DMK6240/MB enable outstanding magnetic resonance imaging capability, as well as amelioration of AD symptoms in vitro and in vivo via the inhibition of hyperphosphorylated tau aggregation and impediment of neuronal death. In conclusion, a tau-targeted drug delivery platform with both disease diagnostics and treatment functions was developed in order to promote new applications of MOFs in the fields of AD and has potential applications in other neurodegenerative diseases.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhao, J., Yin, F., Ji, L., Wang, C., Shi, C., Liu, X., et al. (2020). Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy. ACS applied materials & interfaces. https://doi.org/10.1021/acsami.0c11064
Vancouver
Zhao J, Yin F, Ji L, Wang C, Shi C, Liu X, et al. Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy. ACS applied materials & interfaces. 2020. doi:10.1021/acsami.0c11064. PMID: 32897042.
BibTeX
@article{zhao2020-32897042,
author = {Zhao, J. and Yin, F. and Ji, L. and Wang, C. and Shi, C. and Liu, X. and Yang, H. and Wang, X. and others},
title = {{Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy}},
journal = {ACS applied materials \& interfaces},
year = {2020},
doi = {10.1021/acsami.0c11064},
pmid = {32897042},
url = {https://doi.org/10.1021/acsami.0c11064}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In conclusion, a tau-targeted drug delivery platform with both disease diagnostics and treatment functions was developed in order to promote new applications of MOFs in the fields of AD and has potential applications in other neurodegenerative diseases.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 22 of the 58 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (ACS applied materials & interfaces) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32897042) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 22 of the 58 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.